awmsg logo



cabozantinib (Cometriq®)


Reference No. 577

Publication date:
29/01/2015


Appraisal information

cabozantinib (Cometriq®) 20 mg capsule
cabozantinib (Cometriq®) 80 mg capsule


Company: Swedish Orphan Biovitrum Ltd/TMC Pharma Services Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 19/11/2014
AWMSG meeting date: 17/12/2014
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 4014
Ratification by Welsh Government: 28/01/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (ID56) NICE GUIDANCE ISSUED FEBRUARY 2018 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download